Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gossamer Bio, Inc.GOSS · Entity 6928 | Chief Commercial Officer | August 24, 2026 | August 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gossamer Bio, Inc.
Report date August 24, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.18 · Expires 2036-08-23 | Direct | 5,800,051 |
Reported balance
After 2026-08-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-24 · Grant · Acquired 5,800,051 · Balance 5,800,051 F1: 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2026 Filed Aug 26, 2026 22:11 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 5,800,051 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0002003059-26-000008 · wk-form4_1787782286.xml · derivative · entry 1 Smith Robert Paul JR · CIK 0002003059 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,800,051 Underlying: Common Stock · 5,800,051 shares Expires 2036-08-23 F1 · derivative.exercise_date: 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:19 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 572,000 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0002003059-26-000006 · wk-form4_1774037994.xml · derivative · entry 4 Smith Robert Paul JR · CIK 0002003059 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 572,000 Underlying: Common Stock · 572,000 shares Expires 2035-03-03 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:19 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 562,500 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0002003059-26-000006 · wk-form4_1774037994.xml · derivative · entry 3 Smith Robert Paul JR · CIK 0002003059 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 562,500 Underlying: Common Stock · 562,500 shares Expires 2036-01-01 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:19 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 572,000 | Not disclosed Strike: $1.13 | Not disclosed |
DisclosureSEC source: 0002003059-26-000006 · wk-form4_1774037994.xml · derivative · entry 2 Smith Robert Paul JR · CIK 0002003059 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 572,000 shares Expires 2035-03-03 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:19 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 562,500 | Not disclosed Strike: $2.88 | Not disclosed |
DisclosureSEC source: 0002003059-26-000006 · wk-form4_1774037994.xml · derivative · entry 1 Smith Robert Paul JR · CIK 0002003059 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 562,500 shares Expires 2036-01-01 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:38 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 562,500 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0002003059-26-000003 · wk-form4_1767649136.xml · derivative · entry 3 Smith Robert Paul JR · CIK 0002003059 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 562,500 Underlying: Common Stock · 562,500 shares Expires 2036-01-01 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on January 2, 2027 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:38 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock | 93,750 | $0.00 | $0.00 |
DisclosureSEC source: 0002003059-26-000003 · wk-form4_1767649136.xml · nonDerivative · entry 1 Smith Robert Paul JR · CIK 0002003059 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,898 F1 · shares: Represents restricted stock unit award, which will vest in four equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 20:13 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock | 162,500 | $0.00 | $0.00 |
DisclosureSEC source: 0002003059-25-000004 · wk-form4_1759436021.xml · nonDerivative · entry 1 Smith Robert Paul JR · CIK 0002003059 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,500 F1 · shares: Represents performance stock unit award, which will vest in full upon the earlier of (i) the approval of a new drug application for seralutinib or (ii) a change in control, in either case on or prior to the fourth anniversary of the grant date, and subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:06 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 572,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001728117-25-000013 · wk-form4_1741295198.xml · derivative · entry 1 Smith Robert Paul JR · CIK 0002003059 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 572,000 Underlying: Common Stock · 572,000 shares Expires 2035-03-03 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on March 4, 2026 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| June 17, 2024 Filed Jun 21, 2024 00:20 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | PurchaseCommon Stock | 25,000 | $0.60 | $15,050.00 |
DisclosureSEC source: 0001728117-24-000072 · wk-form4_1718929213.xml · nonDerivative · entry 1 Smith Robert Paul JR · CIK 0002003059 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 25,000 Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 22:12 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 1,500,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001728117-23-000164 · wk-form4_1701814328.xml · derivative · entry 1 Smith Robert Paul JR · CIK 0002003059 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2033-12-03 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on December 4, 2024 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.